La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Editas Medicine Gestione
Gestione criteri di controllo 3/4
Editas Medicine's CEO is Gilmore O’Neill, appointed in Jun 2022, has a tenure of 2.17 years. total yearly compensation is $2.39M, comprised of 26.8% salary and 73.2% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $427.51K. The average tenure of the management team and the board of directors is 1.4 years and 3.7 years respectively.
Informazioni chiave
Gilmore O’Neill
Amministratore delegato
US$2.4m
Compenso totale
| Percentuale dello stipendio del CEO | 26.8% |
| Mandato del CEO | 2.2yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 1.4yrs |
| Durata media del Consiglio di amministrazione | 3.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$193m |
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$2m | US$641k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$195m |
| Jun 30 2023 | n/a | n/a | -US$206m |
| Mar 31 2023 | n/a | n/a | -US$219m |
| Dec 31 2022 | US$9m | US$356k | -US$220m |
Compensazione vs Mercato: Gilmore's total compensation ($USD2.39M) is about average for companies of similar size in the US market ($USD2.44M).
Compensazione vs guadagni: Gilmore's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
Gilmore O’Neill (60 yo)
2.2yrs
Mandato
US$2,392,309
Compensazione
Dr. Gilmore O’Neill, M. B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.2yrs | US$2.39m | 0.13% $ 438.2k | |
| CFO & Executive VP | 1.3yrs | US$2.69m | 0.028% $ 94.7k | |
| Executive VP & Chief Scientific Officer | 1.1yrs | US$1.73m | 0.018% $ 59.3k | |
| Executive VP & Chief Medical Officer | 2.1yrs | US$1.14m | 0.051% $ 172.0k | |
| Co-Founder & Scientific Advisory Board Member | 11.6yrs | Nessun dato | Nessun dato | |
| Co-Founder & Scientific Advisory Board Member | 11.6yrs | Nessun dato | Nessun dato | |
| Executive VP and Chief Technical & Quality Officer | less than a year | Nessun dato | Nessun dato | |
| Corporate Communications & Investor Relations | no data | Nessun dato | Nessun dato | |
| Executive VP & General Counsel | no data | Nessun dato | Nessun dato | |
| Executive VP & Chief People Officer | 1.4yrs | Nessun dato | Nessun dato | |
| Executive VP and Chief Commercial & Strategy Officer | less than a year | Nessun dato | Nessun dato |
1.4yrs
Durata media
60yo
Età media
Gestione esperta: EDIT's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | no data | US$2.39m | 0.13% $ 438.2k | |
| Co-Founder & Scientific Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Co-Founder & Scientific Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Independent Chairman of the Board | 2.9yrs | US$238.24k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$210.56k | 0.0024% $ 8.2k | |
| Independent Director | 6.5yrs | US$231.07k | 0.082% $ 277.6k | |
| Independent Director | 1.3yrs | US$264.88k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$213.06k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$215.06k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$205.56k | 0% $ 0 |
3.7yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: EDIT's board of directors are considered experienced (3.7 years average tenure).